ES2525518T3 - Vacunas virales derivadas de células con niveles reducidos de ADN celular residual - Google Patents

Vacunas virales derivadas de células con niveles reducidos de ADN celular residual Download PDF

Info

Publication number
ES2525518T3
ES2525518T3 ES10075529.7T ES10075529T ES2525518T3 ES 2525518 T3 ES2525518 T3 ES 2525518T3 ES 10075529 T ES10075529 T ES 10075529T ES 2525518 T3 ES2525518 T3 ES 2525518T3
Authority
ES
Spain
Prior art keywords
cells
reduced levels
cellular dna
viral vaccines
vaccines derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10075529.7T
Other languages
English (en)
Inventor
Holger Kost
Jens-Peter Gregersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines GmbH
Original Assignee
Novartis Vaccines and Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525518(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics GmbH filed Critical Novartis Vaccines and Diagnostics GmbH
Application granted granted Critical
Publication of ES2525518T3 publication Critical patent/ES2525518T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una vacuna contra la gripe que comprende proteínas inmunogénicas derivada de un virus de la gripe propagado en cultivo celular, en donde la mencionada vacuna contiene menos de 20 ng/mL de ADN de cultivo celular residual y la longitud del ADN de cultivo celular residual es menor de 200 pares de bases

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES10075529.7T 2005-11-01 2006-11-01 Vacunas virales derivadas de células con niveles reducidos de ADN celular residual Active ES2525518T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
US732786P 2005-11-01

Publications (1)

Publication Number Publication Date
ES2525518T3 true ES2525518T3 (es) 2014-12-26

Family

ID=37969762

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06831855.9T Active ES2359214T5 (es) 2005-11-01 2006-11-01 Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
ES10075529.7T Active ES2525518T3 (es) 2005-11-01 2006-11-01 Vacunas virales derivadas de células con niveles reducidos de ADN celular residual

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES06831855.9T Active ES2359214T5 (es) 2005-11-01 2006-11-01 Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona

Country Status (19)

Country Link
US (2) US10655108B2 (es)
EP (3) EP2301572B1 (es)
JP (5) JP5602366B2 (es)
KR (1) KR20080081254A (es)
CN (2) CN104474543A (es)
AT (1) ATE494906T1 (es)
AU (2) AU2006310171B2 (es)
CA (1) CA2627971A1 (es)
CY (1) CY1111378T1 (es)
DE (1) DE602006019629D1 (es)
DK (1) DK1951296T4 (es)
EA (1) EA014062B1 (es)
ES (2) ES2359214T5 (es)
HK (2) HK1129837A1 (es)
NZ (1) NZ567817A (es)
PL (2) PL1951296T5 (es)
PT (1) PT2301572E (es)
SI (1) SI1951296T2 (es)
WO (1) WO2007052163A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567817A (en) * 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
CA2692200A1 (en) * 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2889042A3 (en) * 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
CA2741961A1 (en) * 2008-11-05 2010-05-14 Glaxosmithkline Biologicals S.A. Novel method
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
CN102648003B (zh) 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
PL2491117T3 (pl) 2009-10-20 2014-05-30 Novartis Ag Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
ES2562818T3 (es) 2010-05-03 2016-03-08 Glaxosmithkline Biologicals S.A. Procedimiento de inactivación del virus de la gripe
JP6072677B2 (ja) 2010-05-06 2017-02-01 ノバルティス アーゲー 微生物の不活化のための有機ペルオキシド化合物
CN103025350A (zh) 2010-05-21 2013-04-03 诺华有限公司 流感病毒的重配方法
PL2575873T3 (pl) 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
CA2801149A1 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
SG188947A1 (en) 2010-08-12 2013-06-28 Yisheng Biopharma Holdings Ltd Method for reducing dna impurities in viral compositions
CA2808965C (en) 2010-08-20 2020-01-07 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
EP2678452B1 (en) 2011-02-25 2016-02-24 Novartis AG Exogenous internal positive control for virus detection
EP3290050B1 (en) 2011-11-03 2019-01-02 Sentinext Therapeutics SDN BHD Vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
ES2628301T3 (es) 2012-03-02 2017-08-02 Seqirus UK Limited Recombinación de virus de gripe
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
MX2015006927A (es) 2012-12-03 2016-02-05 Novartis Ag Redistribucion de virus de la influenza.
CN111334530A (zh) 2013-03-13 2020-06-26 诺华股份有限公司 乙型流感病毒重配
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
BR112015030582A2 (pt) 2013-06-06 2017-08-29 Novartis Ag Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
ES2817928T3 (es) 2013-11-15 2021-04-08 Novartis Ag Eliminación de impurezas de cultivos celulares residuales
TWI688652B (zh) * 2014-05-28 2020-03-21 財團法人國家衛生研究院 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
MX2022006005A (es) 2019-11-18 2022-10-27 Seqirus Pty Ltd Metodo para producir virus de la influenza reagrupados.
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (es) * 1974-01-14 1977-07-15 Sandoz Ag
EP0251575B2 (en) 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (ja) 1991-09-25 2000-11-13 松下電工株式会社 多重伝送システムの割込処理方法
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
ES2235489T3 (es) * 1998-06-01 2005-07-01 Chiron Corporation Uso de polimeros de acido hialuronico para la administracion por las mucosas de antigenos y coadyuvantes de vacunas.
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
DE60014076T2 (de) * 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
AU764368B2 (en) 1999-09-24 2003-08-14 Smithkline Beecham Biologicals (Sa) Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
CA2393469A1 (en) 1999-12-08 2001-06-14 Crucell Holland B.V. Method of administering adenovirus
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
US20040071734A1 (en) * 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
DE10293048T1 (de) 2001-04-27 2003-07-31 Glaxosmithkline Biolog Sa Neuer Impfstoff
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
CA2501975A1 (en) 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
UA92132C2 (ru) 2003-05-28 2010-10-11 Висконсин Алюмни Рисьёч Фаундейшн Высокоактивные рекомбинантные вирусы гриппа для вакцин и генотерапии
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
CA2890962A1 (en) * 2004-09-09 2006-03-16 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Decreasing potential iatrogenic risks associated with influenza vaccines
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
NZ567817A (en) * 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment

Also Published As

Publication number Publication date
PL2301572T3 (pl) 2015-02-27
PL1951296T5 (pl) 2015-06-30
JP2009513694A (ja) 2009-04-02
JP6639077B2 (ja) 2020-02-05
KR20080081254A (ko) 2008-09-09
JP5602366B2 (ja) 2014-10-08
WO2007052163A3 (en) 2007-09-07
JP2014198726A (ja) 2014-10-23
ES2359214T5 (es) 2014-10-08
US20200377864A1 (en) 2020-12-03
HK1129837A1 (en) 2009-12-11
JP7049761B2 (ja) 2022-04-07
DK1951296T4 (da) 2014-09-01
ATE494906T1 (de) 2011-01-15
CA2627971A1 (en) 2007-05-10
ES2359214T3 (es) 2011-05-19
JP2011256209A (ja) 2011-12-22
PL1951296T3 (pl) 2011-09-30
US11466257B2 (en) 2022-10-11
EP1951296B1 (en) 2011-01-12
EP2301572B1 (en) 2014-09-10
NZ567817A (en) 2012-01-12
EP2301572A1 (en) 2011-03-30
PT2301572E (pt) 2014-12-22
WO2007052163A2 (en) 2007-05-10
DE602006019629D1 (de) 2011-02-24
AU2006310171B2 (en) 2011-02-17
JP2016185988A (ja) 2016-10-27
EA014062B1 (ru) 2010-08-30
SI1951296T2 (sl) 2014-09-30
CN104474543A (zh) 2015-04-01
EA200801221A1 (ru) 2008-10-30
HK1207828A1 (en) 2016-02-12
AU2011201968B2 (en) 2014-08-28
CY1111378T1 (el) 2015-08-05
CN101365480A (zh) 2009-02-11
EP1951296B2 (en) 2014-07-23
BRPI0618094A8 (pt) 2017-08-22
AU2011201968A1 (en) 2011-05-19
EP2842572A1 (en) 2015-03-04
AU2006310171A1 (en) 2007-05-10
JP2020023557A (ja) 2020-02-13
US20090304729A1 (en) 2009-12-10
DK1951296T3 (da) 2011-03-28
US10655108B2 (en) 2020-05-19
CN101365480B (zh) 2014-11-05
EP1951296A2 (en) 2008-08-06
SI1951296T1 (sl) 2011-04-29
BRPI0618094A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
ES2525518T3 (es) Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
AR071220A1 (es) Astrovirus aviario depositado bajo el nuero cncm i-3895
RU2487935C2 (ru) Линии клеток почки собаки майдин-дэрби (mdck), поддерживающие рост вирусов до высоких титров, и способ применения этих клеток в биореакторе
DE50214416D1 (de) Vermehrung von viren in zellkultur
NO20023829L (no) Proteosom influensavaksine
ES2129386T1 (es) Vacuna contra influenza.
CY1113875T1 (el) Βελτιστοποιημενη εκφραση hpv 58 l1 σε ζυμομυκητα
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
ES2562774T3 (es) Vacunas para la gripe basadas en el virus del mosaico de la papaya
DK1450856T3 (da) Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
ES2530694T3 (es) Factor de permisividad celular para virus, y usos del mismo
AR049825A1 (es) Vacuna de una subunidad prrsv
ATE544848T1 (de) Cokultur-lte (lymphoid tissue equivalent) für artifizielles immunsystem (ais)
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
BR112022014830A2 (pt) Formulações de vacina para coronavírus
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
FR20C1043I1 (fr) Vaccins avec adjuvants dotés d'antigènes non virioniques préparés à partir de virus de la grippe cultivés dans une culture cellulaire
CL2011000913A1 (es) Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion.
AR057225A1 (es) Vacunas marcadas contra el virus de la diarrea virica bovina
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
CY1109344T1 (el) Εμβολιο αδρανοποιημενου nodavirus
CO5660272A2 (es) Vacunas bovinas con adyuvantes
ES2562919T3 (es) Proteína y secuencia de ADN que codifica una actividad del tipo de la subtilisina adaptada al frío
AR062917A1 (es) Nuevo mutante de pestivirus para uso en una vacuna.